CROI 2017 Abstract e-Book

Abstract eBook

Keyword Index

Cervical cancer 22, 23 Cervical lesions 23 Cervico-vaginal lavage 946 CHAPAS-3` 808 CHARTER 393

Cryotherapy 941 Cryptococcal antigen 345, 740, 741, 742, 743 Cryptococcal meningitis 82, 368, 741, 744, 745, 746 Cryptococcal reactivation 345 Cryptococcosis 82 CSF 82, 369, 382, 398, 746 CTL 119LB Culture Conversion 718 Cumulative viral load 624 Cure 119LB, 124, 272, 296, 299LB, 319, 320, 323, 335, 338LB, 560 CXCR5+ CD8 T cells 266 CYP3A4*22 416 CyPA 160LB, 18 Cytokines 87, 256, 446 Cytomegalovirus 206, 240, 241, 738, 774, 786 Cytoskeleton 169 Cytotoxic T lymphocyte 176, 268, 269, 272, 296, 335 D-dimer 471, 673 DAA 137LB, 551, 566, 567 Dapivirine 88, 501, 935, 951, 952 Darunavir 128LB, 425, 431, 433, 505, 753 Data collection 904 DBS 510, 522 DC-targeting vaccine 262 ddPCR 297, 303, 796 Death 668, 693 Decompensation 534 Decrease 855 Deep sequencing 163, 200, 201, 364, 500LB Defective HIV 296 Depression 362, 455, 746, 920, 922 Diabetes 230, 637, 638, 690, 693, 734 Diagnosis 1026, 493, 508, 509, 549, 711, 747, 76LB, 792, 886, 887 Differentiated care 1051, 1052 Direct-acting antiviral 136, 534, 535, 540, 553, 558, 564, 565, 569, 570, 571 Discontinuation 651, 751 Discordant 794 Discrete choice experiment 895 Disease progression 37, 447 Disengagement 990 Disparity 31, 553, 606, 615, 891, 906, 912 Defective provirus 159 Delayed positivity 793 Democratic Republic of Congo 522 Dendritic cells 250, 333 Depot medroxyprogesterone acetate 944

Dual infection 200, 201, 862 Dual therapy 445, 458 Dynamic compartmental transmission model 875

Dyslipidemia 613, 696 Early diagnosis 1041

Chemokine receptor 288 Chemotherapy 323, 818 Chemsex 567 Child-Pugh 536 Children 424, 487, 726, 784, 801, 802, 811, 815, 818, 819, 823,

Early HIV infection 15, 120, 219, 890 Early infant diagnosis 26, 788, 794 Early transmission events 199 East Africa 837, 860 East Europe 461 Echocardiogram 621 Economic evaluation 129, 547, 1045, 1050 Economic modeling 1028 Efavirenz 384, 423, 442, 454, 455, 697, 783, 819 EFdA 440 EFdA / MK-8591 503 Effectiveness 136, 582, 1050

824, 826, 827, 828, 830, 832, 841LB Chimeric Antigen Receptor 331 China 399 Chlamydia trachomatis 867, 948 Cholesterol 571, 573 Chromatin 308 Chronic diseases 642 Chronic hepatitis C 530, 547

Effector function 270 Efficacy 427, 444, 805 Elastase 660 Electronic medical records 544, 545 Elimination 1042 Elite controller 65, 228, 236, 267, 268 Elite neutralizer 245 Elvitegravir 378, 651, 755 Emergency department 956 Emphysema 655, 658, 659, 660 Empirically derived-risk score 858 Emtricitabine 406 Endothelium 616 Engagement 769 Enteral nutrition 429 Entry inhibition 220, 247, 438, 450LB Env 158, 220, 243, 247, 364, 365 Envelope trimer 246 Epicardial adipose tissue 655 Endothelial dysfunction 641 Endothelial function 589, 825

Chronic HIV infection 254, 344, 692 Chronic Inflammation 610, 827, 828 Chronic kidney disease 653, 687 Chronic lung disease 658 Circumcision 982, 983, 984, 986, 987 Cirrhosis 532, 534, 535, 536, 551, 570, 571

Clinical monitoring 402, 908 Clinical outcomes 402, 470, 623 Clinical pharmacology 29LB, 40, 406 Clinical trial 22, 317, 343, 400, 492, 697, 723LB, 724LB, 79 Clonal expansion 287, 292, 294, 297, 302

Clonal HIV populations 294 Cluster 185, 244, 518, 845LB Clustering 847

Coagulation 608, 825 Cobicistat 410, 425, 755 Cognition 350, 351, 403 Cognitive impairment 341, 355, 394, 399, 827, 828 Cognitive screening tools 355 Cohort 327, 481, 534, 598, 631, 659, 732, 928 Coinfection 587, 735 Collaborative practice agreement 963 Collagen I 251 Combination prevention 34LB, 834, 891, 993, 1009 Community-based HIV testing and counseling 763, 993, 1009 Community-based intervention 1004, 1032, 834, 841LB Comorbidity 133, 235, 620, 643, 646, 653, 663, 670, 671, 672, 929 Compartmentalization 71, 364, 368, 369 Complementary and alternative medicine 669

Keyword Index

Epidemiology 1025, 131, 135, 195, 518, 523, 539, 550, 600, 602, 636LB, 661, 725, 727, 735, 737, 775, 821, 846, 848, 851, 865, 899 · Control 1017, 1053 · Monitoring 885 Epigenetics 228 Epithelial cells 204 Epitope 66, 243 Epstein-Barr virus 240, 604 Eradication 326, 550 Escape 243, 366 ESCRT 20 Estrogen 756 Etonogestrel implant 938 Evolution 20, 120, 192, 195, 197, 243 Ex vivo 122, 944

Completeness 187 Concurrency 843 Condomless sex 918 Continuation phase TB treatment 719 Contraception 88, 423, 938, 942, 943, 946, 1038 Control 638

DLCO 655 DNA 290

Dolutegravir 112, 409a, 41, 410, 42, 426, 429, 432, 44LB, 451LB, 456, 458, 460, 489, 495, 496, 499, 651, 664, 806, 812

Donor resources 1053 Doravirine 412, 45LB Dose reduction 39 Dosing 809

Exercise 616 Exosomes 21 Extrapulmonary samples 713 Failure 468, 565, 566 Falls 361, 665, 666, 930 False positive 992 Family planning 937 Fast-track ART initiation 1008 Fat 700 Fatigue 669 Fatty liver disease 701 Female sex workers 914, 915, 937 Fertility 939, 942 Fetus 753 FIB-4 533 Fibrosis 251, 526, 533, 587, 696 Financial incentives 1045 Financing 1053

Controlled delivery 422LB Controllers 250, 325, 473 COPD 654, 658, 659

Dried blood spots 405, 953 Droplet digital PCR 300, 320 Drug 79 · Delivery 1035 · Discovery 247, 433 · Interactions 409, 409a, 410, 413, 414, 423, 428 · Networks 842 · Regimens 724LB · Resistance 77, 480, 487, 492, 494, 496, 497, 498, 502, 503, 506, 561 · Resistance mutations 43, 370, 481, 484, 490 · Resistance testing 43, 496

Coronary artery calcium 628 Coronary artery plaque 627 Corticosteroids 738 Cost 475, 1031, 1050, 1051 Cost-effectiveness 112, 116, 456, 476, 493, 494, 814, 1028, 1029, 1030, 1032, 1038, 1043, 1045 Cotrimoxazole 705 CPSF6 18 CRISPR-Cas9 19 Cross-resistance 264 Cross-sectional incidence testing 516 Cross-species transmission 190

· Transporter 409 · Use 134, 736, 871 Dual humanized mice 588

CRP 471, 629 Crushing 429

CROI 2017 486